Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
UBS
Covington
Daiichi Sankyo
Express Scripts
Deloitte
Citi
Dow

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,592,365

« Back to Dashboard

Title:Spacer moiety for poly(ethylene glycol) modified peptide based compounds
Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: --NH--(CH.sub.2).sub..alpha.--[O--(CH.sub.2).sub..beta.].sub..gamma.--O.s- ub..delta.--(CH.sub.2).sub..epsilon.--Y-- wherein .alpha., .beta., .gamma., .delta., and .epsilon. are each integers whose values are independently selected.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Tumelty; David (Sunnyvale, CA), Yin; Qun (Palo Alto, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Filing Date:Apr 04, 2011
Application Number:13/079,615
Claims:1. A compound comprising a peptide moiety, a spacer moiety, and a water-soluble polymer moiety wherein: the peptide moiety comprises at least one peptide monomer; the spacer moiety is between the peptide moiety and the water-soluble polymer moiety, and has the structure: --NH--(CH.sub.2).sub..alpha.--[O--(CH.sub.2).sub..beta.].sub..gamma.--O.s- ub..delta.--(CH.sub.2).sub..epsilon.--Y--; .alpha. is an integer, 1.ltoreq..alpha..ltoreq.6; .beta. is an integer, 1.ltoreq..beta..ltoreq.6; .epsilon. is an integer, 1.ltoreq..epsilon..ltoreq.6; .delta. is 0 or 1; .gamma. is an integer, 0.ltoreq..gamma..ltoreq.10; and Y is either NH or CO.

2. The compound of claim 1, wherein the peptide moiety is a peptide monomer comprising a single peptide.

3. The compound of claim 1, wherein the peptide moiety comprises two peptide monomers linked by a linker moiety.

4. The compound of claim 1, wherein the peptide moiety comprises one or more peptides which bind to thrombopoietin-receptors.

5. A pharmaceutical composition comprising (a) a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety; and (b) one or more pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants or carriers wherein: the peptide moiety comprises at least one peptide monomer, the spacer moiety is between the peptide moiety and the water-soluble polymer moiety and has the structure: --NH--(CH.sub.2).sub..alpha.--[O--(CH.sub.2).sub..beta.].sub..gamma.--O.s- ub..delta.--(CH.sub.2).sub..epsilon.--Y-- .alpha. is an integer, 1.ltoreq..alpha..ltoreq.6; .beta. is an integer, 1.ltoreq..beta..ltoreq.6; .epsilon. is an integer, 1.ltoreq..epsilon..ltoreq.6; .delta. is 0 or 1; .gamma. is an integer, 0.ltoreq..gamma..ltoreq.10; and Y is either NH or CO.

6. The composition of claim 5, wherein the peptide moiety is peptide monomer comprising a single peptide.

7. The composition of claim 5, wherein the peptide moiety comprises two peptide monomers linked by a linker moiety.

8. The composition of claim 5, wherein the peptide moiety comprises one or more peptides which bind to thrombopoietin-receptors.

9. The compound according to claim 3, wherein the linker moiety has the structure ##STR00005## N of the linker moiety is covalently attached to Y of the spacer moiety, Y of the spacer moiety is CO, and .eta. and .phi. are integers whose values are independently selected.

10. The composition according to claim 7, wherein the linker moiety has the structure ##STR00006## N of the linker moiety is covalently attached to Y of the spacer moiety, Y of the spacer moiety is CO, and .eta. and .phi. are integers whose values are independently selected.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Farmers Insurance
AstraZeneca
Dow
Cerilliant
Queensland Health
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.